Canaccord Genuity Maintains Buy on Orthofix Medical, Lowers Price Target to $13
Canaccord Genuity analyst Caitlin Burrows maintains Orthofix Medical (NASDAQ:OFIX) with a Buy and lowers the price target from $18 to $13.
Read original at benzingaStocks · News reference
Orthofix shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 5, 2026, 12:48 PM
- Checked
- Aug 5, 2026, 12:48 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Orthofix Medical Inc. (OFIX)
Filed: 2026-08-05 AccNo: 0001193125-26-333817 Size: 30 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarOrthofix Medical Raises FY2026 Sales Guidance from $838.000M-$848.000M to $845.000M-$855.000M vs $843.311M Est
Orthofix Medical (NASDAQ:OFIX) raises FY2026 sales outlook from $838.000 million-$848.000 million to $845.000 million-$855.000 million vs $843.311 million estimate.
Read original at benzinga